Kenneth Galbraith - Jan 5, 2024 Form 4 Insider Report for Zymeworks Inc. (ZYME)

Signature
/s/ Daniel Dex, Attorney-in-Fact
Stock symbol
ZYME
Transactions as of
Jan 5, 2024
Transactions value $
-$257,845
Form type
4
Date filed
1/8/2024, 06:23 PM
Previous filing
Jan 6, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZYME Common Stock Options Exercise $0 +47.7K $0.00 47.7K Jan 5, 2024 Direct F1
transaction ZYME Common Stock Sale -$194K -18.2K -38.18% $10.65 29.5K Jan 5, 2024 Direct F2, F3
transaction ZYME Common Stock Sale -$64K -5.71K -19.36% $11.22 23.8K Jan 8, 2024 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZYME Restricted Stock Unit Options Exercise $0 -47.7K -33.33% $0.00 95.3K Jan 5, 2024 Common Stock 47.7K Direct F5, F6
transaction ZYME Stock Option (Right to Buy) Award $0 +300K $0.00 300K Jan 5, 2024 Common Stock 300K $10.56 Direct F7
transaction ZYME Restricted Stock Unit Award $0 +200K $0.00 200K Jan 5, 2024 Common Stock 200K Direct F5, F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon vesting of one third of the restricted stock units ("RSUs") granted on January 5, 2023.
F2 Represents shares of common stock sold to cover tax withholding obligations and other applicable fees in connection with the vesting of RSUs pursuant to mandatory "sell to cover" provisions contained in the Reporting Person's applicable RSU grant agreement, and does not represent a discretionary sale by the Reporting Person. The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.55 to $10.845, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.49 to $11.58, inclusive. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F5 Each RSU represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock.
F6 The RSUS were granted on January 5, 2023 and vest in three equal annual installments beginning on January 5, 2024.
F7 Stock options vest as follows: (i) 25% of underlying shares of common stock on first anniversary of grant date and (ii) remainder of underlying shares of common stock in 36 equal monthly installments on last day of month following first anniversary of grant date.
F8 The RSUs vest in three equal annual installments beginning on January 5, 2025.